secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001493152-23-040499
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences reports Q3 2023 net loss of $2.82M; cash $4.27M; advances psychedelic pipeline
--------------------------------------------------------------------------------

- Net loss of $2.82M ($1.30 per share) vs $2.60M ($1.46 per share) in Q3 2022.
- Cash and cash equivalents of $4.27M as of Sept 30, 2023.
- Granted two US patents for EVM301 Series and EB-373; filed six non-US applications.
- Completed manufacturing of EB-373; preclinical data show oral bioavailability and safety.
- AI drug discovery engine Psybrary surpassed 1,000 compounds analyzed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315223040499/0001493152-23-040499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315223040499/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer